Skip to main content
Top
Published in: Inflammation 1/2012

01-02-2012

Proinflammatory CD14+CD16+ Monocytes are Associated with Microinflammation in Patients with Type 2 Diabetes Mellitus and Diabetic Nephropathy Uremia

Authors: Mengxue Yang, Hua Gan, Qing Shen, Weixue Tang, Xiaogang Du, Danyan Chen

Published in: Inflammation | Issue 1/2012

Login to get access

Abstract

Diabetic nephropathy (DN) is a major cause of type 2 diabetes mellitus (T2DM) mortality. Innate immunity has been shown to be closely associated with the occurrence and progression of T2DM-associated complications. In this study, we investigated the expression of Toll-like receptor 4 (TLR4) and CD14+CD16+ monocytes in patients with T2DM and DN patients with uremia and TLR4 response to lipopolysaccharide (LPS), and to further explore the potential effects of inflammatory immune response in T2DM and DN uremia. Thirty DN patients with uremia, 28 T2DM patients, and 20 healthy volunteers were enrolled for the determination of CD14+CD16+ fluorescence intensity and TLR4 expression on monocytes by using peripheral blood flow cytometry. Serum C-reactive protein (CRP) level was determined by using the immunoturbidimetry. Peripheral blood mononuclear cells (PBMCs) were isolated and stimulated with LPS for 24 h. monocytes were collected to detect NF-κB p65 and phosphorylated STAT5(p-STAT5) expressions by using Western blotting. Supernatants were sampled for the determination of interleukin-6 (IL-6) concentration by using ELISA. Compared to normal control, T2DM patients and DN uremic patients had a significantly higher CD14+CD16+ fluorescence intensity, TLR4 expression, serum IL-6 and CRP level, whilst these biomarkers were more upregulated in DN uremic patients than in T2DM patients. Following the exposure to LPS, PBMCs showed a significant upregulation in NF-κB-p65 and p-STAT5 expression and a remarked increase in Supernatants IL-6 level, in a positive correlation with disease severity. Our results suggest that the disturbance in proinflammatory CD14+CD16+ monocytes occurs in T2DM and DN uremic patients. Such immunological dysfunction may be related to the activation of TLR4/NF-κB and STAT5 signaling pathways underlying the immune abnormalities of CD14+CD16+ monocytes.
Literature
1.
go back to reference Navarro-González, J.F., and C. Mora-Fernández. 2008. The role of inflammatory cytokines in diabetic nephropathy. Journal of the American Society of Nephrologists 19(3): 433–442.CrossRef Navarro-González, J.F., and C. Mora-Fernández. 2008. The role of inflammatory cytokines in diabetic nephropathy. Journal of the American Society of Nephrologists 19(3): 433–442.CrossRef
2.
go back to reference Ortiz-Muñoz, G., V. Lopez-Parra, O. Lopez-Franco, et al. 2010. Suppressors of cytokine signaling abrogate diabetic nephropathy. Journal of the American Society of Nephrologists 21: 763–772.CrossRef Ortiz-Muñoz, G., V. Lopez-Parra, O. Lopez-Franco, et al. 2010. Suppressors of cytokine signaling abrogate diabetic nephropathy. Journal of the American Society of Nephrologists 21: 763–772.CrossRef
3.
go back to reference O’Connor, J.C., A. Satpathy, M.E. Hartman, et al. 2005. IL-β mediated innate immunity is amplified in the db/db mouse model of type 2 diabetes. Journal of Immunology 174(8): 4991–4997. O’Connor, J.C., A. Satpathy, M.E. Hartman, et al. 2005. IL-β mediated innate immunity is amplified in the db/db mouse model of type 2 diabetes. Journal of Immunology 174(8): 4991–4997.
4.
go back to reference Ko, G.J., Y.S. Kang, S.Y. Han, et al. 2008. Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. Nephrology, Dialysis, Transplantation 23(9): 2750–2760.PubMedCrossRef Ko, G.J., Y.S. Kang, S.Y. Han, et al. 2008. Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. Nephrology, Dialysis, Transplantation 23(9): 2750–2760.PubMedCrossRef
5.
go back to reference Mora, C., and J.F. Navarro. 2006. Inflammation and diabetic nephropathy. Current Diabetes Reports 6(6): 463–468.PubMedCrossRef Mora, C., and J.F. Navarro. 2006. Inflammation and diabetic nephropathy. Current Diabetes Reports 6(6): 463–468.PubMedCrossRef
6.
go back to reference Navarro, J.F., and C. Mora. 2006. Diabetes, inflammation, proinflammatory cytokines, and diabetic nephropathy. The Scientific World Journal 6: 908–917.CrossRef Navarro, J.F., and C. Mora. 2006. Diabetes, inflammation, proinflammatory cytokines, and diabetic nephropathy. The Scientific World Journal 6: 908–917.CrossRef
7.
go back to reference Tuttle, K.R. 2005. Linking metabolism and immunology: diabetic nephropathyis an inflammatory disease. Journal of the American Society of Nephrologists 16(6): 1537–1538.CrossRef Tuttle, K.R. 2005. Linking metabolism and immunology: diabetic nephropathyis an inflammatory disease. Journal of the American Society of Nephrologists 16(6): 1537–1538.CrossRef
8.
go back to reference Kikuchi, Y., T. Imakiire, M. Yamada, et al. 2005. Mizoribine reduces renal injury and macrophage infiltration in non-insulin dependent diabetic rats. Nephrology, Dialysis, Transplantation 20(8): 1573–1581.PubMedCrossRef Kikuchi, Y., T. Imakiire, M. Yamada, et al. 2005. Mizoribine reduces renal injury and macrophage infiltration in non-insulin dependent diabetic rats. Nephrology, Dialysis, Transplantation 20(8): 1573–1581.PubMedCrossRef
9.
go back to reference Giulietti, A., E. van Etten, L. Overbergh, et al. 2007. Monocytes from type 2 diabetic patients have a pro-inflammatory profile 1,25-dihydroxyvitamin D3 works as anti-inflammatory. Diabetes Research and Clinical Practice 77: 47–57.PubMedCrossRef Giulietti, A., E. van Etten, L. Overbergh, et al. 2007. Monocytes from type 2 diabetic patients have a pro-inflammatory profile 1,25-dihydroxyvitamin D3 works as anti-inflammatory. Diabetes Research and Clinical Practice 77: 47–57.PubMedCrossRef
10.
go back to reference Ruster, C., and G. Wolf. 2008. The role of chemokines and chemokine receptors in diabetic nephropathy. Frontiers of Bioscience 13: 944–955.CrossRef Ruster, C., and G. Wolf. 2008. The role of chemokines and chemokine receptors in diabetic nephropathy. Frontiers of Bioscience 13: 944–955.CrossRef
11.
go back to reference Chow, F., E. Ozols, D.J. Nikolic-Paterson, et al. 2004. Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state, and progressive renal injury. Kidney International 65: 116–128.PubMedCrossRef Chow, F., E. Ozols, D.J. Nikolic-Paterson, et al. 2004. Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state, and progressive renal injury. Kidney International 65: 116–128.PubMedCrossRef
12.
go back to reference Furuta, T., T. Saito, T. Ootaka, et al. 1993. The role of macrophages in diabetic glomerulosclerosis. American Journal of Kidney Diseases 21: 480–485.PubMed Furuta, T., T. Saito, T. Ootaka, et al. 1993. The role of macrophages in diabetic glomerulosclerosis. American Journal of Kidney Diseases 21: 480–485.PubMed
13.
go back to reference Utimura, R., C.K. Fujihara, A.L. Mattar, et al. 2003. Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes. Kidney International 63: 209–216.PubMedCrossRef Utimura, R., C.K. Fujihara, A.L. Mattar, et al. 2003. Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes. Kidney International 63: 209–216.PubMedCrossRef
14.
go back to reference ManLi, L., G. Hua, and Q. Lin. 2009. The expression of TLR4 on peripheral blood monocytes from uremic patients with diabetic nephropathy and its relation with plasma MCP-1 concentration. China Immunology Journal 25(9): 848–850. ManLi, L., G. Hua, and Q. Lin. 2009. The expression of TLR4 on peripheral blood monocytes from uremic patients with diabetic nephropathy and its relation with plasma MCP-1 concentration. China Immunology Journal 25(9): 848–850.
15.
go back to reference Hypponen, E., B.J. Boucher, D.J. Berry, et al. 2008. 25-Hydroxyvitamin D, IGF-1, and metabolic syndrome at 45 years of age: a cross sectional study in the 1958 British Birth Cohort. Diabetes 57(2): 298–305.PubMedCrossRef Hypponen, E., B.J. Boucher, D.J. Berry, et al. 2008. 25-Hydroxyvitamin D, IGF-1, and metabolic syndrome at 45 years of age: a cross sectional study in the 1958 British Birth Cohort. Diabetes 57(2): 298–305.PubMedCrossRef
16.
go back to reference Devaraj, S., J.-M. Yun, C.R. Duncan-Staley, et al. 2011. Low vitamin D levels correlate with the proinflammatory state in type 1 diabetic subjects with and without microvascular complications. American Society for Clinical Pathology 135: 429–433.CrossRef Devaraj, S., J.-M. Yun, C.R. Duncan-Staley, et al. 2011. Low vitamin D levels correlate with the proinflammatory state in type 1 diabetic subjects with and without microvascular complications. American Society for Clinical Pathology 135: 429–433.CrossRef
17.
go back to reference Ozfirat, Z., and T.A. Chowdhury. 2010. Vitamin D deficiency and type 2 diabetes. Postgraduate Medical Journal 86: 18–25.PubMedCrossRef Ozfirat, Z., and T.A. Chowdhury. 2010. Vitamin D deficiency and type 2 diabetes. Postgraduate Medical Journal 86: 18–25.PubMedCrossRef
18.
go back to reference Kayaniyil, S., R. Vieth, R. Retnakaran, et al. 2010. Association of vitamin D with insulin resistance and β-cell dysfunction in subjects at risk for type 2 diabetes. Diabetes Care 33(6): 1379–1381.PubMedCrossRef Kayaniyil, S., R. Vieth, R. Retnakaran, et al. 2010. Association of vitamin D with insulin resistance and β-cell dysfunction in subjects at risk for type 2 diabetes. Diabetes Care 33(6): 1379–1381.PubMedCrossRef
19.
go back to reference Di Cesar, D.J., R. Ploutz-Snyder, R.S. Weinstock, et al. 2006. Vitamin D deficiency is more common in type 2 than in type 1 diabetes. Diabetes Care 29(1): 174.PubMedCrossRef Di Cesar, D.J., R. Ploutz-Snyder, R.S. Weinstock, et al. 2006. Vitamin D deficiency is more common in type 2 than in type 1 diabetes. Diabetes Care 29(1): 174.PubMedCrossRef
20.
go back to reference Du, T., Z.-G. Zhou, S. You, et al. 2009. Modulation of monocyte hyperresponsiveness to TLR ligands by 1,25-dihydroxy-vitamin D3 from LADA and T2DM. Diabetes Research and Clinical Practice 83(2): 208–214.PubMedCrossRef Du, T., Z.-G. Zhou, S. You, et al. 2009. Modulation of monocyte hyperresponsiveness to TLR ligands by 1,25-dihydroxy-vitamin D3 from LADA and T2DM. Diabetes Research and Clinical Practice 83(2): 208–214.PubMedCrossRef
21.
go back to reference Sadeghi, K., B. Wessner, U. Laggner, et al. 2006. Vitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns. European Journal of Immunology 36: 361–370.PubMedCrossRef Sadeghi, K., B. Wessner, U. Laggner, et al. 2006. Vitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns. European Journal of Immunology 36: 361–370.PubMedCrossRef
22.
go back to reference Ziegler-Heitbrock, L. 2007. The CD14+CD16+ blood monocytes: their role in infection and inflammation. Journal of Leukocyte Biology 81: 584–592.PubMedCrossRef Ziegler-Heitbrock, L. 2007. The CD14+CD16+ blood monocytes: their role in infection and inflammation. Journal of Leukocyte Biology 81: 584–592.PubMedCrossRef
23.
go back to reference Patino, R., J. Ibarra, A. Rodriguez, et al. 2000. Circulating monocytes in patients with diabetes mellitus, arterial disease, and increased CD14 expression. The American Journal of Cardiology 85: 1288–1291.PubMedCrossRef Patino, R., J. Ibarra, A. Rodriguez, et al. 2000. Circulating monocytes in patients with diabetes mellitus, arterial disease, and increased CD14 expression. The American Journal of Cardiology 85: 1288–1291.PubMedCrossRef
24.
go back to reference Ulrich, C., G.H. Heine, M.K. Gerhart, et al. 2008. Proinflammatory CD14+CD16+ monocytes are associated with subclinical atherosclerosis in renal transplant patients. American Journal of Transplantation 8(1): 103–110.PubMedCrossRef Ulrich, C., G.H. Heine, M.K. Gerhart, et al. 2008. Proinflammatory CD14+CD16+ monocytes are associated with subclinical atherosclerosis in renal transplant patients. American Journal of Transplantation 8(1): 103–110.PubMedCrossRef
25.
go back to reference Barisione, C., S. Garibaldi, G. Ghigliotti, et al. 2010. CD14CD16 monocyte subset levels in heart failure patients. Disease Markers 28(2): 115–124.PubMed Barisione, C., S. Garibaldi, G. Ghigliotti, et al. 2010. CD14CD16 monocyte subset levels in heart failure patients. Disease Markers 28(2): 115–124.PubMed
26.
go back to reference Pettersson, A., A. Sabirsh, J. Bristulf, et al. 2005. Pro- and anti-inflammatory substances modulate expression of the leukotriene B4 receptor, BLT1, in human monocytes. Journal of Leukocyte Biology 77: 1018–1025.PubMedCrossRef Pettersson, A., A. Sabirsh, J. Bristulf, et al. 2005. Pro- and anti-inflammatory substances modulate expression of the leukotriene B4 receptor, BLT1, in human monocytes. Journal of Leukocyte Biology 77: 1018–1025.PubMedCrossRef
27.
go back to reference Rogacev, K.S., S. Seiler, A.M. Zawada, et al. 2011. CD14++CD16+ monocytes and cardiovascular outcome in patients with chronic kidney disease. European Heart Journal 32(1): 84–92.PubMedCrossRef Rogacev, K.S., S. Seiler, A.M. Zawada, et al. 2011. CD14++CD16+ monocytes and cardiovascular outcome in patients with chronic kidney disease. European Heart Journal 32(1): 84–92.PubMedCrossRef
28.
go back to reference Tripathi, P., S. Kurtulus, S. Wojciechowski, et al. 2010. STAT5 is critical to maintain effector CD8+ T cell responses. Journal of Immunology 185: 2116–2124.CrossRef Tripathi, P., S. Kurtulus, S. Wojciechowski, et al. 2010. STAT5 is critical to maintain effector CD8+ T cell responses. Journal of Immunology 185: 2116–2124.CrossRef
Metadata
Title
Proinflammatory CD14+CD16+ Monocytes are Associated with Microinflammation in Patients with Type 2 Diabetes Mellitus and Diabetic Nephropathy Uremia
Authors
Mengxue Yang
Hua Gan
Qing Shen
Weixue Tang
Xiaogang Du
Danyan Chen
Publication date
01-02-2012
Publisher
Springer US
Published in
Inflammation / Issue 1/2012
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-011-9374-9

Other articles of this Issue 1/2012

Inflammation 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine